文献速递前列腺癌

多西他赛/泼尼松联合或不联合贝伐珠单抗治疗的转移性去势抵抗性前列腺癌男性血浆循环生物标志物的预后与预测分析

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-02-12

CALGB 90401(Alliance)是一项III期试验,纳入1050例转移性去势抵抗性前列腺癌(mCRPC)患者,比较多西他赛+泼尼松+贝伐珠单抗(DP+B)与单用DP。该试验未显示总生存(OS)改善,但中间结局改善提示部分患者可能从联合治疗中获益。本分析旨在识别与DP+B的OS和无进展生存(PFS)获益相关的预后和预测生物标志物。

要点

  • 15种标志物可预后OS,9种同时可预后PFS。
  • 多变量分析中7种标志物与OS相关(FDR<0.1)。
  • 骨桥蛋白(OPN)在未校正分析中预测DP+B的PFS改善。

核心结论

  • 在CALGB 90401中识别出多种可预后临床结局的生物标志物,但未发现可预测OS的生物标志物。
  • OPN可能作为抗血管生成治疗的潜在生物标志物,但需进一步机制和临床研究以确定其生物学基础及潜在临床应用。

研究设计与样本

  • CALGB 90401(Alliance)是一项III期试验,纳入1050例mCRPC患者,比较多西他赛+泼尼松+贝伐珠单抗(DP+B)与单用DP。
  • 本分析对650例同意患者的基线EDTA血浆样本检测24种生物标志物,采用比例风险模型检验其预后和预测重要性。

主要发现

  • 15种标志物(ICAM-1、VEGF-R3、TIMP-1、TSP-2、Ang-2、Her-3、OPN、PlGF、VCAM-1、HGF、VEGF、嗜铬粒蛋白A、IL-6、VEGF-R1、BMP-9)可预后OS。
  • 9种标志物(ICAM-1、VEGF-R3、Her-3、TIMP-1、Ang-2、OPN、PlGF、HGF、VEGF)也可预后PFS。
  • 所有标志物在单变量分析中经多重性校正后均有统计学意义(FDR<0.1)。
  • 在调整风险评分后的OS多变量分析中,7种标志物FDR<0.1,包括ICAM-1、VEGF-R3、TIMP-1、Ang-2、VEGF、TSP-2和HGF。
  • 在未校正分析中,OPN在单变量和多变量分析中均预测DP+B的PFS改善。

关键数值与推荐

  • 15种标志物可预后OS,9种同时可预后PFS,所有标志物单变量分析FDR<0.1。
  • OS多变量分析中7种标志物FDR<0.1。
  • OPN在未校正分析中预测DP+B的PFS改善,但校正多重比较后无标志物可预测临床结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • OPN作为抗血管生成治疗的潜在生物标志物需进一步机制和临床研究以确定其生物学基础及潜在临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in overall survival (OS), there were improved intermediate outcomes suggesting that subsets of men may derive benefit from this combination. The purpose of this analysis was to identify prognostic and predictive biomarkers associated with OS and progression-free survival (PFS) benefit from DP+B. METHODS: Baseline EDTA plasma samples from 650 consenting patients were analyzed for 24 biomarkers. The proportional hazards model was utilized to test for the prognostic and predictive importance of the biomarkers for OS. The statistically significant biomarkers of OS were further investigated for prognostic and predictive importance for other secondary outcomes. RESULTS: 15 markers [ICAM-1, VEGF-R3, TIMP-1, TSP-2, Ang-2, Her-3, Osteopontin (OPN), PlGF, VCAM-1, HGF, VEGF, Chromogranin A, IL-6, VEGF-R1, BMP-9] were prognostic of OS, while 9 markers (ICAM-1, VEGF-R3, Her-3, TIMP-1, Ang-2, OPN, PlGF, HGF, and VEGF) were also prognostic of PFS. All markers were statistically significant in univariate analyses after adjustment for multiplicity (FDR < 0.1). In multivariable analyses of OS adjusting for risk score, seven markers had FDR < 0.1, including ICAM-1, VEGF-R3, TIMP-1, Ang-2, VEGF, TSP-2 and HGF. In unadjusted analysis, OPN was predictive of PFS improvement with DP+B, in both univariate and multivariable analysis. However, none of the biomarkers tested were predictive of clinical outcomes after adjusting for multiple comparisons. CONCLUSIONS: Multiple biomarkers were identified in CALGB 90401 as prognostic of clinical outcomes but not predictive of OS. While OPN may have promise as a potential biomarker for anti-angiogenic therapies, further mechanistic and clinical studies are needed to determine the underlying biology and potential clinical application.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Nixon AB, Liu Y, Yang Q, et al. Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. Prostate Cancer Prostatic Dis. 2024. PMID: 38347114. doi:10.1038/s41391-024-00794-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。